Showing results (101-110 of 410) with videos related to

Sort By:
Pageof 41
Pediatric Blood & Cancer|September 17, 2022
Imaging recommendations in pediatric lymphoma: A COG Diagnostic Imaging Committee/SPR Oncology Committee White PaperJoyce Mhlanga, Adina Alazraki, Steve Y Cho, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 31, 2018
Biodistribution and radiation dose estimates for 68Ga-DOTA-JR11 in patients with metastatic neuroendocrine tumorsSimone Krebs, Neeta Pandit-Taskar, Diane Reidy, et al.
Neuro-Oncology|February 19, 2025
Phase 1 dose-escalation trial using convection-enhanced delivery (CED) of radio-immunotheranostic 124I-Omburtamab for diffuse intrinsic pontine glioma (DIPG)Mark M Souweidane, Evan D Bander, Pat Zanzonico, et al.
Journal of Neuro-Oncology|May 7, 2015
Low incidence of radionecrosis in children treated with conventional radiation therapy and intrathecal radioimmunotherapyKim Kramer, Neeta Pandit-Taskar, Pat Zanzonico, et al.
Current Pharmaceutical Design|March 12, 2009
Cancer drug development with the help of radiopharmaceuticals: academic experienceSteven M Larson
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 5, 2019
Do You Want an Inspirational Career? Choose Nuclear MedicineSteven M Larson
BMC Medical Imaging|April 28, 2017
A comparison of pediatric and adult CT organ dose estimation methodsYiming Gao, Brian Quinn, Usman Mahmood, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|June 5, 2014
Impact of pre-operative positron emission tomography in gallbladder cancerUniverse Leung, Neeta Pandit-Taskar, Carlos U Corvera, et al.
Radiology|August 11, 2010
Recurrent ovarian cancer: use of contrast-enhanced CT and PET/CT to accurately localize tumor recurrence and to predict patients' survivalEvis Sala, Masako Kataoka, Neeta Pandit-Taskar, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 8, 2020
Comparison of 68Ga-DOTA-JR11 PET/CT with dosimetric 177Lu-satoreotide tetraxetan (177Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapySimone Krebs, Joseph A O'Donoghue, Evan Biegel, et al.
Pageof 41